Terry Bowers, MD
Cardiovascular Disease · Troy, MINPI 1972586758
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $159,663 of the $254,822 with a category attached, or 62.7%. 28 manufacturers reported payments, led by Imperative Care, Inc at 37.5% of the total. Reporting peaked in 2022 at $82,606 and has fallen 58.0% since, to $34,679 in 2025. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 427 payments — averaging $596.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Imperative Care, Inc$96K
- Johnson & Johnson$67K
- Truvic Medical, Inc.$58K
- Boston Scientific$11K
- Pfizer$9K
- E.r. Squibb & Sons, L.L.C.$8K
- plus $6K from 22 others
Across 36 payments — averaging $1094.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inari Medical, Inc.$39K
What the payments were for
- Consulting fees$159,66363%
- Speaking & faculty fees$77,84531%
- Travel & lodging$5,7732%
- Food & beverage$11,5365%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Imperative Care, Inc | 45 | $95,521 |
| Johnson & Johnson | 137 | $67,300 |
| Truvic Medical, Inc. | 16 | $58,253 |
| Boston Scientific | 27 | $10,630 |
| Pfizer | 26 | $9,288 |
| E.r. Squibb & Sons, L.L.C. | 21 | $7,641 |
| Inari Medical, Inc. | 14 | $3,084 |
| Amgen | 30 | $493 |
| Novartis | 29 | $404 |
| Boehringer Ingelheim | 15 | $340 |
| Angiodynamics, Inc. | 2 | $279 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $246 |
| Medtronic(2 entities) | 7 | $231 |
| Sanofi-aventis U.S. LLC | 10 | $217 |
| Abbott | 3 | $176 |
| Penumbra, Inc. | 1 | $142 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Amarin Pharma, Inc. | 7 | $114 |
| AstraZeneca | 5 | $61 |
| Alnylam Pharmaceuticals Inc. | 4 | $60 |
| Bayer | 2 | $50 |
| Gilead | 3 | $44 |
| Bard Peripheral Vascular, Inc. | 1 | $27 |
| Merck | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Bardy Diagnostics, Inc. | 1 | $18 |
| Shockwave Medical, Inc | 1 | $17 |
| Preventice Services, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZOOM 88-T LARGE DISTAL PLATFORM$91,461
- XARELTO$65,867
- ELIQUIS$16,415
- GENERAL - THERAPIES$9,600
- SYMPHONY CATHETER$3,446
- FLOWTRIEVER CATHETER, S$2,398
- CT THROMBECTOMY SYSTEM KIT$2,398
- FlowTriever$380
- ClotTriever$380
- EKOSONIC$242
- AlphaVac$190
- ELUVIA$161
- Indigo System$142
- XIENCE ALPINE$140
- IN.PACT Admiral$139
- PRODIGY CATHETER$127
- GLADIATOR ELITE$119
- PRALUENT$109
How this compares
$254,822 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 503 | $677,978 |
| XareltoRivaroxaban | 371 | $492,113 |
| EntrestoSacubitril/Valsartan | 120 | $188,960 |
| Repatha SureclickEvolocumab | 238 | $169,611 |
| JardianceEmpagliflozin | 42 | $52,049 |
| Praluent PenAlirocumab | 34 | $29,251 |
| Ranolazine ErRanolazine | 136 | $16,925 |
| Metoprolol Succinate | 824 | $15,071 |
| BrilintaTicagrelor | 13 | $13,707 |
| Atorvastatin Calcium | 855 | $13,015 |
| Carvedilol | 786 | $11,646 |
| Rosuvastatin Calcium | 658 | $11,211 |
| Losartan Potassium | 700 | $10,147 |
| Repatha PushtronexEvolocumab | 15 | $8,861 |
| ClopidogrelClopidogrel Bisulfate | 408 | $7,213 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $9,288 | $677,978503 claims |
| Johnson & JohnsonXarelto | $67,300 | $492,113371 claims |
| NovartisEntresto | $404 | $188,960120 claims |
| Boehringer IngelheimJardiance | $340 | $52,04942 claims |
| AstraZenecaBrilinta | $61 | $13,70713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Troy
- Steven AlmanyTroy$471K
- Michael GallagherTroy$284K
- Steven AjluniTroy$55K
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- David StroblLansing$445K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.